Investigating the function of group 3 innate lymphoid cells in the renal tract
Investigating the function of group 3 innate lymphoid cells in the renal tract
批准号:
MR/N024907/1
负责人:
Menna Clatworthy
金额:
$79.27万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The kidneys play a critical role in cleaning the blood and controlling the body's water balance. Unfortunately, their function can be affected by a number of common diseases that can be life-threatening, including infection. Urinary tract infections (UTIs) are common, affecting up to half of women at some point in their lifetime. Recurrent infections can cause scarring that leads to permanent kidney damage and even kidney failure. All of the body's tissues house cells of the immune system. These sentinels stand guard in tissues and alert the body to infection by starting an inflammatory response. In the kidney, the response of immune sentinels to infection or tissue damage determines the extent of inflammation, and this can influence whether bacteria are cleared, whether there is collateral damage, and ultimately whether the function of the kidneys recovers or develops scarring. At present, we don't fully understand what type of tissue-resident immune cells live in human kidneys and bladder or their exact function. Addressing this challenge will help us to development better treatments for diseases that affect the kidney, including UTIs.In the last 5 years, a new family of immune cells have been discovered, the innate lymphoid cells (ILCs). These cells act as tissue sentinels, producing chemical signals (cytokines) that activate the immune system. One member of the ILC family, the ILC3s, have been found to be enriched in the intestine where they prevent the invasion of bacteria from the gut and produce factors that maintain the health of tissue cells. There is currently no information on whether there are ILC3s in human kidneys and bladder. We were interested in finding out if ILC3s could be important in these tissues and performed some preliminary experiments. Excitingly, we found ILC3s in mouse and human kidneys and bladder.The objective of this project is to find out what exactly they are doing, as follows:1. Where ILC3s are positioned in kidneys and bladder and whether they are situated near other immune sentinels.2. What sort of immune signalling molecules (chemokines and cytokines) are produced by ILC3s at during health and in response to the bacteria that cause UTIs. We can use mouse models and human tissues that have been donated for transplant, but cannot be used.3. How ILC3s patrol the kidney and bladder and whether they form interactions with other immune cells. To answer this question we will use a special sort of microscope and mice that have fluorescently labelled ILC3s. We have developed a protocol that allows us to image the cells in real time in the kidney and bladder, so we can begin to investigate the factors that control their movement and their interactions with other immune cells.4. Whether outcome and disease severity in UTI is affected by an absence of ILC3s, using mice that lack ILC3s due to genetic deletion of a factor that is required for their development.Elucidating the workings of ILC3s will help us to understand whether they contribute to helpful immune responses that clear bacteria in the renal tract. This will being to enable us to harness their useful functions to develop better therapeutic strategies that might reduce the frequency of UTIs or the scarring that can be associated with recurrent infections. In the long run, this could prevent patients from getting kidney failure and could help prolong the life of kidney transplants, which can also be damaged by recurrent infection.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Mucosal IgG in inflammatory bowel disease - a question of (sub)class?
炎症性肠病中的粘膜 IgG——(亚)类问题?
DOI:
10.17863/cam.43332
发表时间:
2020
期刊:
影响因子:
--
作者:
[Castro-Dopico T]
通讯作者:
Castro-Dopico T
GM-CSF Calibrates Macrophage Defense and Wound Healing Programs during Intestinal Infection and Inflammation.
GM-CSF 在肠道感染和炎症期间校准巨噬细胞防御和伤口愈合程序。
DOI:
10.17863/cam.53966
发表时间:
2020
期刊:
影响因子:
--
作者:
[Castro-Dopico T]
通讯作者:
Castro-Dopico T
DOI:
10.17863/cam.40120
发表时间:
2019
期刊:
影响因子:
--
作者:
[Bagchi-Chakraborty J]
通讯作者:
Bagchi-Chakraborty J
Bromodomain Inhibitors Modulate Fc?R-Mediated Mononuclear Phagocyte Activation and Chemotaxis.
Bromodomain 抑制剂调节 Fc?R 介导的单核吞噬细胞激活和趋化性。
DOI:
10.17863/cam.84831
发表时间:
2022
期刊:
影响因子:
--
作者:
[Banham G]
通讯作者:
Banham G
DOI:
10.17863/cam.38374
发表时间:
2019
期刊:
影响因子:
--
作者:
[Castro-Dopico T]
通讯作者:
Castro-Dopico T
Mapping tissue immunity in the human urinary bladder across lifespan
-
批准号:BB/X000249/1
-
项目类别:Research Grant
-
资助金额:$73.29万
-
财政年份:2022
-
负责人:Menna Clatworthy
-
依托单位:
Defining regional anatomical variation in cellular composition, transcriptome and epigenome in the human kidney
-
批准号:MR/S035842/1
-
项目类别:Research Grant
-
资助金额:$56.28万
-
财政年份:2019
-
负责人:Menna Clatworthy
-
依托单位:
国内基金
海外基金
登录
查看更多内容
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
Idh3a作为线粒体代谢—表观遗传检查点调控产热脂肪功能的机制研究
-
批准号:82370851
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:包玉倩
-
依托单位:
基于再生运动神经路径优化Agrin作用促进损伤神经靶向投射的功能研究
-
批准号:82371373
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:沃雁
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
GASP-1通过Myostatin信号通路调控颏舌肌功能的作用及机制研究
-
批准号:82371131
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:易红良
-
依托单位:
双硫仑结合并抑制谷氨酸脱氢酶1活性调节Th17/Treg细胞平衡的作用与机制探究
-
批准号:82371755
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王秦兰
-
依托单位:
犬尿氨酸酶KYNU参与非酒精性脂肪肝进展为肝纤维化的作用和机制研究
-
批准号:82370874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘才智
-
依托单位: